The Global Health Body Sounds Warning Over Acute Shortage of Obesity Jabs

Under one in 10 patients eligible to benefit from GLP-1 drugs including Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the therapies.

Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer access to this class of drugs.

Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.

"Our latest guidelines affirms that obesity is a long-term condition that can be addressed with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are key obstacles to widespread access to the jabs that can aid individuals in losing considerable weight, says the body.

Weight-Loss Drug Shortage

Despite the present most optimistic case, the supply of these medications could only cover around 100 million people – under 10% of eligible patients, as stated by the WHO.

The advice urges nations and manufacturers to expand access, through measures including licensing agreements.

Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.

The Way Obesity Injections Operate

The injections mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals eat less.

Patients typically begin shedding pounds after several weeks of starting on the regular doses.

Evidence indicates users may regain a significant portion a year later of halting the drug, when their typical food cravings return.

To be overweight or obese elevates your risk for contracting diseases, like diabetes, cardiovascular issues, stroke, and some malignancies.

Obesity affects individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.